^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iCAR-ILC-N101

    i
    Other names: iCAR-ILC-N101, GPC3-CAR expressing iPS cell-derived innate lymphoid/natural killer cells
    Associations

    News

    Trials
    Company:
    National Cancer Center Hospital East
    Drug class:
    GPC-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    First in human trial of off-the shelf iPS derived anti-GPC3 NK cells for recurrent ovarian clear cell carcinoma with peritoneal dissemination (AACR 2022)
    The iCAR-ILC-N101 is an allogeneic human leukocyte antigen (HLA)-homozygous induced pluripotent stem cell (iPSC)-derived anti-glypican-3 (GPC3) CAR-expressing innate lymphoid cells/natural killer cell (ILC/NK), which has both antigen-specific and NK activating receptor-mediated cytotoxicity...No dose-limiting toxicity was observed. Clinical trial registry number: jRCT2033200431
    P1 data
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    iCAR-ILC-N101